Avidity Biosciences — Technical Presentation (June 2024)
47 slides from Avidity Biosciences's technical presentation, Jun 12, 2024
Slide 1: Transforming FSHD: AOC 1020 FORTITUDE Phase 1/2 Initial Data
1 June 12, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 9 Transforming Facioscapulohumeral Muscular Dystrophy (FSHD) AOC 1020 FORTITUDETM Phase 1/2 Initial Data
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking state
Slide 3: Our Vision
3 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Amy Living with FSHD Amy Living with FSHD
Slide 4: Revolutionizing New Class of Targeted RNA Therapeutics
4 Revolutionizing New Class of Targeted RNA Therapeutics AOC platform delivers reproducible, consistent data across muscle disease programs Rare Muscle Disease Therapies in Development Clinical Program Safety & Tolerability Delivery to Muscle Target Engagement Functional Improvement Facioscapulohume
Slide 5: Purpose of Update
5 Purpose of Update Present Initial Data from Phase 1/2 FORTITUDE Del-brax 2 mg/kg at 4 months • Unprecedented and consistent reduction in DUX4- regulated genes • Signs of functional improvement: muscle strength; increased reachable workspace; positive patient and clinician reported outcomes • Favor
Slide 6: Del-brax: Transforming the Treatment of FSHD
6 Del-brax: Transforming the Treatment of FSHD First-in-class and best-in-class: greater than 50% reduction in DUX4 regulated genes Accelerating Del-brax Toward Approval Unprecedented & Consistent Reduction in DUX4 Regulated Genes Signs of Functional Improvement and Reported Outcomes Favorable Saf
Slide 7: Avidity Management Team and Guest Speaker
7 Jeffrey M. Statland, M.D. Professor of Neurology, University of Kansas Medical Center Steve Hughes, M.D. Chief Medical Officer Sarah Boyce President & CEO W. Michael Flanagan, Ph.D. Chief Scientific & Technical Officer Geoff Grande, CFA VP, Investor Relations & Corporate Communications Transformin
Slide 8: Agenda/Outline
8 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Delivering for People Living with FSHD Steve Hughes, M.D., CMO Leading the Field: Directly Targeting DUX4 Michael Flanagan, Ph.D., CSO & CTO FORTITUDETM Preliminary Data Assessment Jeffrey M. Statland, M.D., Professor
Slide 9: Facioscapulohumeral Muscular Dystrophy (FSHD)
9 Facioscapulohumeral Muscular Dystrophy (FSHD) Rare, hereditary disorder causing relentless loss of muscle function and progressive disability • One of the most common forms of muscular dystrophy • FSHD causes progressive muscle weakness, pain, fatigue and disability • Onset typically occurs in tee
Slide 10: Phase 1/2 FORTITUDE Trial
10 Phase 1/2 FORTITUDE Trial Initial data presented today from 2 mg/kg cohort at 4 months • Pharmacodynamics • Biomarkers • Measures of clinical activity • Muscle strength • Muscle function • Muscle composition (MRI) • Patient and Clinician reported outcomes Key Exploratory Objectives • Randomized,
Slide 11: Baseline Demographics Generally Well Matched Between Groups
11 Baseline Demographics Generally Well Matched Between Groups Cohort A Placebo N=4 % or mean (SD) Del-brax 2 mg/kg* N=8 % or mean (SD) Sex, % Male 75 62.5 Age, years 53.5 (10.15) 51.6 (11.62) Genetic Diagnosis, % FSHD 1 100 100 FSHD Clinical Score 9.3 (1.71) 9.3 (2.31) D4Z4 Repeat Number 5.0 (2.45)
Slide 12: Del-brax: Favorable Safety and Tolerability
12 Del-brax: Favorable Safety and Tolerability Subjects with ≥ 1 AE n (%) Placebo N=13 2 mg/kg* N=8 4 mg/kg N=18 Any AE 11 (84.6%) 8 (100%) 17 (94.4%) Related to study drug 3 (23.1%) 4 (50%) 9 (50%) Severe AE 0 0 0 Serious AE (SAE) 0 0 0 AE leading to study discontinuation 0 0 0 AE leading to death
Slide 13: Accelerating Del-brax Registrational Plan
13 Accelerating Del-brax Registrational Plan Pulling forward registrational cohorts Dose Booster Muscle biopsies to be performed at Baseline and 4 monthsMultidose quarterly with 1 booster after first 6 weeks; Dose listed is siRNA * Participants receive a first dose of 1mg/kg and then receive the 2mg
Slide 14: Agenda/Outline
14 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Delivering for People Living with FSHD Steve Hughes, M.D., CMO Leading the Field: Directly Targeting DUX4 Michael Flanagan, Ph.D., CSO & CTO FORTITUDETM Preliminary Data Assessment Jeffrey M. Statland, M.D., Professor
Slide 15: Del-brax: Transforming the Treatment of FSHD
15 Del-brax: Transforming the Treatment of FSHD Connecting the dots from delivery to function Delivery to Muscle Reduction in DUX4 Gene Signature Impact on FSHD Disease Biology Decrease in Novel Circulating Biomarker • Consistent and effective delivery of siRNA to muscle • Reinforcing the disruptive
Slide 16: Del-brax: Targets DUX4, the Root Cause of FSHD
16 Del-brax: Targets DUX4, the Root Cause of FSHD Targets aberrant expression of DUX4 mRNA for destruction FSHD disease pathology1,2 Del-brax Therapeutic Hypothesis 1 Lemmers RJLF, et al. Science 329:1650–1653 (2010) 2 Snider L, et al. PLoS Genet. 2010;6(10):e1001181;
Slide 17: Consistent and Effective Delivery of siRNA to Muscle
17 Del-brax: Consistent and Effective Delivery of siRNA to Muscle 1,2 mg/kg 0.1 1 10 si R N A M us cl e C on c. (n M ) n=7 2 mg/kg* Muscle biopsies were collected in leg muscles (vastus lateralis, vastus medialis, tibialis anterior, gastrocnemius medialis or gastrocnemius lateralis) with fat fractio
Slide 18: DUX4-Regulated Genes Selected for Robustness and Reproducibility
18 DUX4-Regulated Genes Selected for Robustness and Reproducibility Procured muscle biopsies, RNA sequencing, patient-derived cells informed the panel LEUTX TRIM43 KHDC1L MBD3L2 Avidity Gene Panel Validated qPCR assay RNA sequencing from healthy muscle biopsies RNA sequencing from FSHD muscle biopsi
Slide 19: Del-brax Demonstrates Meaningful 53% Reduction in DUX4-regulated Genes
19 Del-brax Demonstrates Meaningful 53% Reduction in DUX4-regulated Genes All del-brax treated participants showed reductions >20% in DUX4 regulated genes 41-Gene Panel3 ReDux4 Panel2 53% (12 mg/kg) • All del-brax treated participants showed greater than 20% reduction in DUX4 regulated genes • All
Slide 20: Consistent >50% Reductions in DUX4-regulated Genes Across Panels
20 -100 -75 -50 -25 0 D U X4 s co re * (% C ha ng e fr om B as el in e) PBO AOC 1020 (1 & 2 mg/kg) -100 -75 -50 -25 0 D U X4 s co re * (% C ha ng e fr om B as el in e) PBO AOC 1020 (1 & 2 mg/kg) -100 -75 -50 -25 0 D U X4 s co re * (% C ha ng e fr om B as el in e) PBO AOC 1020 (1 & 2 mg/kg) Del-brax
Slide 21: Del-brax Impacts Underlying FSHD Disease Biology
21 Del-brax Impacts Underlying FSHD Disease Biology Broad biological effects following del-brax treatment Dux4 Differential gene expression (excluding DUX4 regulated genes) in muscle utilizing RNASeq. N=7 del-brax 1 mg/kg (D1), 2 mg/kg (D43 and D92). One participant missed post-dose biopsy. Each col
Slide 22: Circulating Biomarkers Provide Early Detection of Whole-Body Response
22 Circulating Biomarkers Provide Early Detection of Whole-Body Response to Del-brax Treatment • Sampling of single muscle • Limited timepoints • Invasive • Comprehensive assessment throughout body • Continuous monitoring • Patient friendly Muscle Biopsy Circulating Biomarker
Slide 23: Novel DUX4-Regulated Circulating Biomarker
23 Advisors & Disease Expertise FSHD & Healthy Biopsies Plasma from FSHD & Healthy Volunteers Novel DUX4-Regulated Circulating Biomarker Potential accelerated approval endpoint Potential Accelerated Approval Endpoint • Significantly elevated in patients with FSHD as compared to healthy individuals •
Slide 24: Early and Sustained Reduction of Novel Circulating Biomarker
24 Del-brax Shows Early and Sustained Reduction of a Novel DUX4-Regulated Circulating Biomarker Del-brax treatment shows 25% reduction in circulating biomarker in participants with FSHD versus placebo PBO del-brax 2 mg/kg* 0 1 2 3 4 -40 -20 0 20 Study Month % C ha ng e fro m B as el in e AOC 1020 (1
Slide 25: Decrease in Novel and Creatine Kinase Circulating Biomarkers
25 Consistent and Confirmatory Decrease in Both Novel and Creatine Kinase Circulating Biomarkers Decreases in creatine kinase, an indicator of muscle damage 0 1 2 3 4 -40 -20 0 20 Study Month % C ha ng e fr om B as el in e AOC 1020 (1 & 2 mg/kg) PBO Novel DUX4-regulated biomarker Creatine kinase bio
Slide 26: Del-brax: Transforming the Treatment of FSHD
26 Del-brax: Transforming the Treatment of FSHD Connecting the dots from delivery to function Delivery to Muscle Reduction in DUX4 Gene Signature Impact on FSHD Disease Biology Decrease in Novel Circulating Biomarker • Consistent and effective delivery of siRNA to muscle • Reinforcing the disruptive
Slide 27: Agenda/Outline
27 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Delivering for People Living with FSHD Steve Hughes, M.D., CMO Leading the Field: Directly Targeting DUX4 Michael Flanagan, Ph.D., CSO & CTO FORTITUDETM Preliminary Data Assessment Jeffrey M. Statland, M.D., Professor
Slide 28: Jeffrey M. Statland, M.D. Biography
28 Jeffrey M. Statland, M.D. is a Professor of Neurology at the University of Kansas Medical Center in Kansas City, Kansas. His research background has centered primarily on describing the natural history of and response to therapy for neuromuscular diseases. He completed a neuromuscular fellowship
Slide 29: Clinical Features of FSHD
29 Rosenberg, R. N., & Pascual, J. M. (2020). Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease: Volume 2 . Huisinga J, et al. Muscle Nerve. 2018 Mar;57(3):503-506. doi: 10.1002/mus.25955. Epub 2017 Oct 6. PMID: 28877559; PMCID: PMC6631361. Clinical Features of FSHD • I
Slide 30: FSHD Causes Progressive Muscle Weakness
30 • Illustration shows typical early (pink) and later muscle involvement (blue) • Approximately 60% of adults presenting symptom is inability to reach above the shoulder height • The next most common presenting symptom in adults is foot drop • About 20% of individuals will lose the ability to walk
Slide 31: Impact of Living with FSHD
31 Impact of Living with FSHD n=1147 McNiff et al. J Neuromuscul Dis. 2024;11(2):459-472. General muscle weakness Difficulty using arms or hands Not being able to walk or impaired mobility Fatigue, energy and endurance Not having the energy to work or live as I want to Losing mobility/ability to wal
Slide 32: Exploratory Endpoints: Muscle Strength, Range of Motion and Function, Reported Outcomes
Exploratory Endpoints: Muscle Strength, Range of Motion and Function, Patient and Clinician Reported Outcomes
Slide 33: Del-brax Improved Muscle Strength in Both Upper and Lower Limb
33 Del-brax Improved Muscle Strength in Both Upper and Lower Limb ImprovingDeclining Placebo del-brax 2 mg/kg* Total Composite Ankle Dorsiflexion Shoulder Abductor -10 -5 0 5 -20 -10 0 10 -40 -20 0 20 Change from Baseline to Month 4 (Mean ± SEM) Percent Predicted Normal QMT by hand-held device Total
Slide 34: Reachable Workspace: Validated Measurement of Upper Extremity Function
34 Reachable Workspace (RWS): Validated Measurement of Quantifying Improvement in Upper Extremity Range of Motion and Function RWS correlates with ability to perform activities of daily living and maintain independence Video depicts healthy person demonstrating RWS Q1 Q3 Q2 Q4 Q3 Q4 Q5 Bioniks websi
Slide 35: Del-brax Improved Reachable Workspace Compared to Placebo
35 Del-brax Improved Reachable Workspace Compared to Placebo Improved range of motion and function; similar trends observed without weight Placebo del-brax 2 mg/kg* Q1 Q3 Q2 Q4 Q3 Q4 Q5 Change from Baseline to Month 4 (Mean ±SEM) Relative Surface Area Average n=8 & Dominant n=7 in the AOC group * Pa
Slide 36: ReSolve Observational Study
36 ReSolve (NCT03458832): 24 Months Observational Study • Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD (ReSolve) • FSHD Clinical Trial Research Network: at 11 centers in the US and EU • Goal: to hasten drug development for FSHD by validating new clinical outcome assessments
Slide 37: Improved Reachable Workspace Compared to Matched Natural History Data
37 Del-brax Improved Reachable Workspace Compared to Matched Natural History Data Reachable Workspace Q1-5; Dominant Arm; Weight: 500 g 2 mg/kg FORTITUDE (4 Mo) N=7^ RESOLVE Natural History (3 mo) N=63 ImprovingDeclining Natural history study del-brax 2 mg/kg* -0.025 0.000 0.025 0.050 0.075 Thanks t
Slide 38: Positive Trends in Patient and Clinician Reported Outcome Measures
38 Del-brax: Positive Trends Toward Improvement in Both Patient and Clinician Reported Outcome Measures CGI-C; CGI-S (Clinician Global Impression of Change; Severity) PGI-C; PGI-S (Patient Global Impression of Change; Severity) *first dose 1 mg/kg CGI-S CGI-C Clinician Reported Outcome Measures Chan
Slide 39: Del-brax: Promising New Potential Treatment for Patients with FSHD
39 Del-brax: Promising New Potential Treatment for Patients with FSHD • Effective muscle delivery with unprecedented and consistent >50% reduction in DUX4 regulated gene panels – impacting underlying FSHD disease biology • Decrease in circulating biomarkers (novel and creatine kinase) indicate whole
Slide 40: Agenda/Outline
40 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Delivering for People Living with FSHD Steve Hughes, M.D., CMO Leading the Field: Directly Targeting DUX4 Michael Flanagan, Ph.D., CSO & CTO FORTITUDETM Preliminary Data Assessment Jeffrey M. Statland, M.D., Professor
Slide 41: Del-brax: Transforming the Treatment of FSHD
41 Del-brax: Transforming the Treatment of FSHD First-in-class and best-in-class: greater than 50% reduction in DUX4 regulated genes Accelerating Del-brax Toward Approval Unprecedented & Consistent Reduction in DUX4 Regulated Genes Signs of Functional Improvement and Reported Outcomes Favorable Sa
Slide 42: Delivering on the RNA Revolution
42 Delivering on the RNA Revolution
Slide 43: Delivering in 2024: Data Readouts in 3 Rare Diseases
43 Delivering in 2024: 3 Data Readouts in 3 Clinical Programs in 3 Rare Diseases Del-desiran in DM1 >40,000 patients in U.S. MARINA-OLE data (Q1 2024) Initiation of global Phase 3 HARBOR trial (Q2 2024) Del-brax in FSHD ~16,000-38,000 patients in U.S. Phase 1/2 FORTITUDE initial data (Q2 2024) AOC 1
Slide 44: Our Vision
44 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Amy Living with FSHD Amy Living with FSHD
Slide 45: Q&A
45 June 12, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 9 Transforming Facioscapulohumeral Muscular Dystrophy (FSHD) AOC 1020 FORTITUDETM Phase 1/2 Initial Data Q&A
Slide 46: Our Vision
46 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Amy Living with FSHD Amy Living with FSHD
Slide 47: Transforming FSHD: AOC 1020 FORTITUDE Phase 1/2 Initial Data
47 June 12, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 9 Transforming Facioscapulohumeral Muscular Dystrophy (FSHD) AOC 1020 FORTITUDETM Phase 1/2 Initial Data
Avidity Biosciences — Technical Presentation (June 2024) on 6ix